Femasys gets Australian & New Zealand approvals for FemaSeed and FemVue

FEMASYS INC

Regulatory approvals granted for FemaSeed first-line intratubal insemination treatment and FemVue diagnostic.
CEO Kathy Lee-Sepsick cites expanded global access and meaningful commercial opportunities.
Approvals validate clinical value of platform and reinforce commitment to accessible infertility solutions.
Company expects to grow revenue and broaden global footprint with these regulatory milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.